OncoMatch/Clinical Trials/NCT06739226
Combination Immunotherapy Targeting Melanoma
Is NCT06739226 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Antigen-specific CAR T, CTL and DCvac to treat melanoma. for melanoma.
Treatment: Antigen-specific CAR T, CTL and DCvac to treat melanoma. — The purpose of this study is to assess the feasibility, safety and efficacy of combination immunotherapy based on CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines modified with GM-CSF and B7-2 (CD86) against melanoma, which targets CAR T specific surface antigens such as GD2, CTL specific antigens such as MAGE-A4, gp100 and a pool of melanoma specific antigens presented by the DCs. Another goal of the study is to learn more about the function and persistence of the CAR T cells and antigen-specific immune effectors in patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Metastatic disease required
Prior therapy
Must have received: standard first-line therapy
Patients with melanoma have received standard first-line therapy
Cannot have received: genetically engineered CAR T cells
Previous treatment with other genetically engineered CAR T cells.
Lab requirements
Blood counts
white blood cell count ≥1000/ul, absolute neutrophil count ≥500/ul, absolute lymphocyte count ≥500/ul, platelet count ≥25,000/ul (not achieved by transfusion)
Kidney function
serum creatinine less than 3 times uln
Liver function
alt <3x uln, ast <3x uln; serum bilirubin and alkaline phosphatase <2x uln
Cardiac function
left ventricular ejection fraction greater than or equal to 40/55 percent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify